Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Fineline Cube Dec 30, 2025
Company Drug

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL

Fineline Cube Apr 18, 2025

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company Deals

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment

Fineline Cube Apr 18, 2025

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...

Company

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment

Fineline Cube Apr 18, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has completed a 70,000-square-foot expansion at its Myerstown,...

Company Drug

Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China

Fineline Cube Apr 18, 2025

The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...

Company Deals

Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102

Fineline Cube Apr 18, 2025

Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into...

Company Drug

Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes

Fineline Cube Apr 18, 2025

U.S. pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has announced positive top-line results from...

Company Drug

3SBio’s 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China

Fineline Cube Apr 18, 2025

China-based 3SBio Inc. (HKG: 1530) has announced the receipt of Breakthrough Therapy Designation (BTD) from...

Company Deals

NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development

Fineline Cube Apr 18, 2025

NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed...

Company

La Prairie Holistic Health’s Functional Nutrient Product Approved in Hainan Pilot Zone

Fineline Cube Apr 18, 2025

Switzerland-based Clinique La Prairie Holistic Health SA has received approval for its functional nutrient product...

Company Drug

GSK’s Arexvy RSV Vaccine Receives Favorable ACIP Vote for Adults Aged 50-59

Fineline Cube Apr 18, 2025

UK-based pharmaceutical major GlaxoSmithKline (GSK, NYSE: GSK) has announced a favorable vote from the US...

Company Drug

Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy

Fineline Cube Apr 18, 2025

China-based Gene Cradle has received approval from the National Medical Products Administration (NMPA) to proceed...

Company Medical Device

Medtronic’s Implantable Defibrillator System Gains NMPA Approval in China

Fineline Cube Apr 18, 2025

China’s National Medical Products Administration (NMPA) has approved Medtronic’s (NYSE: MDT) endovascular implantable defibrillation electrode...

Company Drug

Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study

Fineline Cube Apr 18, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase...

Company Deals

Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice

Fineline Cube Apr 18, 2025

US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to...

Company Deals Medical Device

Junion Therapeutics Secures RMB 100 Million Series A Financing for Weight Loss Device

Fineline Cube Apr 18, 2025

China-based Junion Therapeutics (Xiamen) Co., Ltd has reportedly secured RMB 100 million (USD 13.7 million)...

Company Deals Drug

Eli Lilly Collaborates with BigHat Biosciences to Engineer Advanced Therapeutic Antibodies

Fineline Cube Apr 18, 2025

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has entered into a collaboration with...

Company Drug

Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer

Fineline Cube Apr 18, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...

Company Drug

GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment

Fineline Cube Apr 18, 2025

UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK) has announced the receipt of...

Company Drug

Salubris Pharma’s YOLT-101 Gene Editing Drug Accepted for NMPA Review

Fineline Cube Apr 18, 2025

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that the National Medical Products Administration...

Company Drug

Hansoh’s HS-20093 ADC Earns BTD for Advanced NSCLC from China’s NMPA

Fineline Cube Apr 18, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that China’s National Medical Products...

Posts pagination

1 … 112 113 114 … 602

Recent updates

  • J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial
  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.